PALO ALTO, Calif., Oct. 23, 2019 /PRNewswire/ -- Varian (NYSE:
VAR) today announced it has been selected by Penn Medicine to
install a Varian ProBeam® 360° proton therapy system in
a single-room configuration at Lancaster General Health Ann B.
Barshinger Cancer Institute in south central Pennsylvania. In addition to the equipment,
Varian will also provide its ARIA® information
management system and Eclipse™ treatment planning
system. Construction of the new center began in September 2019, with the first patient treatments
expected in 2021.
In addition to the agreement on the proton therapy system, Penn
Medicine and Varian also signed a research collaboration agreement.
The goal of the collaboration is to enable global clinics to
more easily adopt, use, and innovate modern proton therapy
techniques.
With a 30 percent smaller footprint than the previous system,
ProBeam 360° offers uncompromised clinical capabilities while
reducing vault construction costs by approximately 25 percent. The
new system has a 360-degree rotating gantry, the most powerful
particle accelerator available today to treat cancer, iterative
cone-beam CT imaging, and high-definition pencil-beam scanning
technology. The system can also provide clinicians a viable path to
potential next-generation treatments such as FLASH therapy.
The 360-degree rotating gantry of ProBeam 360° enables efficient
Intensity Modulated Proton Therapy (IMPT), and faster treatment
times by minimizing patient repositioning and re-imaging and
allowing high-quality cone beam CT (CBCT) imaging from almost any
angle. RapidScan™ technology, available on the ProBeam 360°,
simplifies the process of motion management by delivering each
field in a single breath-hold. This capability increases the number
of patients who can comply with breath-hold treatments like lung
SBRT.
"We look forward to continuing our strong partnership with Penn
Medicine on the installation of the ProBeam 360° system and
increasing access to this advanced technology," said Kolleen Kennedy, chief growth officer and
president of Proton Therapy Solutions, Varian.
About Varian
At Varian, we envision a world without fear of cancer. For more
than 70 years, we have developed, built and delivered innovative
cancer care technologies and solutions for our clinical partners
around the globe to help them treat millions of patients each year.
With an Intelligent Cancer Care approach, we are harnessing
advanced technologies like artificial intelligence, machine
learning and data analytics to enhance cancer treatment and expand
access to care. Our 9,200 employees across 70 countries keep the
patient and our clinical partners at the center of our thinking as
we power new victories in cancer care. Because, for cancer patients
everywhere, their fight is our fight. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-probeam-360-proton-therapy-system-selected-by-penn-medicine-for-use-in-second-treatment-center-300943915.html
SOURCE Varian